A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain

Nature Structural and Molecular Biology

Volumn 17, Issue 4, 2010, Pages 519-527

  Wojcik, John ^a   Hantschel, Oliver ^b   Grebien, Florian ^b   Kaupe, Ines ^b   Bennett, Keiryn L ^b   Barkinge, John ^c,d   Jones, Richard B ^c,d   Koide, Akiko ^a   Superti Furga, Giulio ^b   Koide, Shohei ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; PROTEIN SH2; STAT5 PROTEIN;

ARTICLE; CRYSTAL STRUCTURE; HUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS V-ABL; PHOSPHORYLATION; SEQUENCE HOMOLOGY, AMINO ACID; SRC HOMOLOGY DOMAINS;

EID: 77950502609     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1793     Document Type: Article

References (58)

1. Pawson, T. & Nash, P. Assembly of cell regulatory systems through protein interaction domains. Science 300, 445-452 (2003).
2. Rual, J.F. et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437, 1173-1178 (2005).
3. Kocher, T. & Superti-Furga, G. Mass spectrometry-based functional proteomics: from molecular machines to protein networks. Nat. Methods 4, 807-815 (2007).
4. Jones, R.B., Gordus, A., Krall, J.A. & MacBeath, G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174 (2006). (Pubitemid 43083134)
5. Weiss, W.A., Taylor, S.S. & Shokat, K.M. Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat. Chem. Biol. 3, 739-744 (2007).
6. Visintin, M., Melchionna, T., Cannistraci, I. & Cattaneo, A. In vivo selection of intrabodies specifcally targeting protein-protein interactions: a general platform for an "undruggable" class of disease targets. J. Biotechnol. 135, 1-15 (2008).
7. Campbell, S.J. & Jackson, R.M. Diversity in the SH2 domain family phosphotyrosyl peptide binding site. Protein Eng. 16, 217-227 (2003).
8. Bradshaw, J.M., Mitaxov, V. & Waksman, G. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase. J. Mol. Biol. 293, 971-985 (1999).
9. Ladbury, J.E. & Arold, S. Searching for specifcity in SH domains. Chem. Biol. 7, R3-R8 (2000).
10. Taylor, J.D. et al. Structure, dynamics, and binding thermodynamics of the v-Src SH2 domain: implications for drug design. Proteins 73, 929-940 (2008).
11. Gan, W. & Roux, B. Binding specifcity of SH2 domains: insight from free energy simulations. Proteins 74, 996-1007 (2009).
12. Shakespeare, W.C. SH2 domain inhibition: a problem solved? Curr. Opin. Chem. Biol. 5, 409-415 (2001).
13. Machida, K. & Mayer, B.J. The SH2 domain: versatile signaling module and pharmaceutical target. Biochim. Biophys. Acta 1747, 1-25 (2005).
14. Mandine, E. et al. High-affnity Src-SH2 ligands which do not activate Tyr(527)-phosphorylated Src in an experimental in vivo system. Biochem. Biophys. Res. Commun. 298, 185-192 (2002).
15. Garcia-Echeverria, C. Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. Curr. Med. Chem. 8, 1589-1604 (2001).
16. Reichert, J.M., Rosensweig, C.J., Faden, L.B. & Dewitz, M.C. Monoclonal antibody successes in the clinic. Nat. Biotechnol. 23, 1073-1078 (2005).
17. Koide, A., Bailey, C.W., Huang, X. & Koide, S. The fbronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284, 1141-1151 (1998).
18. Koide, A., Abbatiello, S., Rothgery, L. & Koide, S. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc. Natl. Acad. Sci. USA 99, 1253-1258 (2002).
19. Gilbreth, R.N., Esaki, K., Koide, A., Sidhu, S.S. & Koide, S. A dominant conformational role for amino acid diversity in minimalist protein-protein interfaces. J. Mol. Biol. 381, 407-418 (2008).
20. Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830 (1990).
21. Nagar, B. et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol. Cell 21, 787-798 (2006).
22. Hantschel, O. & Superti-Furga, G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33-44 (2004). (Pubitemid 38089839)
23. Filippakopoulos, P. et al. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134, 793-803 (2008).
24. Hackel, B.J., Kapila, A. & Wittrup, K.D. Picomolar affnity fbronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffing. J. Mol. Biol. 381, 1238-1252 (2008).
25. Tokonzaba, E., Capelluto, D.G., Kutateladze, T.G. & Overduin, M. Phosphoinositide, phosphopeptide and pyridone interactions of the Abl SH2 domain. Chem. Biol. Drug Des. 67, 230-237 (2006).
26. Porter, C.J. et al. Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation. BMC Struct. Biol. 7, 58 (2007).
27. Burckstummer, T. et al. An effcient tandem affnity purifcation procedure for interaction proteomics in mammalian cells. Nat. Methods 3, 1013-1019 (2006).
28. Brehme, M. et al. Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 106, 7414-7419 (2009).
29. Basu, D., El-Assal Sel, D., Le, J., Mallery, E.L. & Szymanski, D.B. Interchangeable functions of Arabidopsis PIROGI and the human WAVE complex subunit SRA1 during leaf epidermal development. Development 131, 4345-4355 (2004).
30. Ewing, R.M. et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol. 3, 89 (2007).
31. Wu, C. et al. Systematic identifcation of SH3 domain-mediated human protein-protein interactions by peptide array target screening. Proteomics 7, 1775-1785 (2007).
32. MacPartlin, M., Smith, A.M., Druker, B.J., Honigberg, L.A. & Deininger, M.W. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia 22, 1354-1360 (2008).
33. Pendergast, A.M. et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75, 175-185 (1993).
34. Hantschel, O. et al. The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol. Oncol. 2, 272-281 (2008).
35. El Hader, C. et al. HCaRG increases renal cell migration by a TGF-α autocrine loop mechanism. Am. J. Physiol. Renal Physiol. 289, F1273-F1280 (2005).
36. Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871 (2003).
37. Overduin, M., Rios, C.B., Mayer, B.J., Baltimore, D. & Cowburn, D. Three-dimensional solution structure of the src homology 2 domain of c-abl. Cell 70, 697-704 (1992).
38. Waksman, G., Shoelson, S.E., Pant, N., Cowburn, D. & Kuriyan, J. Binding of a high affnity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 72, 779-790 (1993).
39. Eck, M.J., Shoelson, S.E. & Harrison, S.C. Recognition of a high-affnity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Nature 362, 87-91 (1993).
40. Lawrence, M.C. & Colman, P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
41. Hantschel, O. et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845-857 (2003).
42. Patwardhan, P. & Miller, W.T. Processive phosphorylation: mechanism and biological importance. Cell. Signal. 19, 2218-2226 (2007).
43. Schaller, M.D. & Schaefer, E.M. Multiple stimuli induce tyrosine phosphorylation of the Crk-binding sites of paxillin. Biochem. J. 360, 57-66 (2001).
44. Mayer, B.J., Hirai, H. & Sakai, R. Evidence that SH2 domains promote processive phosphorylation by protein-tyrosine kinases. Curr. Biol. 5, 296-305 (1995).
45. Ye, D., Wolff, N., Li, L., Zhang, S. & Ilaria, R.L. Jr. STAT5 signaling is required for the effcient induction and maintenance of CML in mice. Blood 107, 4917-4925 (2006).
46. Nieborowska-Skorska, M. et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189, 1229-1242 (1999).
47. Schoepfer, J. et al. Highly potent inhibitors of the Grb2-SH2 domain. Bioorg. Med. Chem. Lett. 9, 221-226 (1999).
48. Poy, F. et al. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol. Cell 4, 555-561 (1999).
49. Bae, J.H. et al. The selectivity of receptor tyrosine kinase signaling is controlled by a secondary SH2 domain binding site. Cell 138, 514-524 (2009).
50. Fellouse, F.A. et al. High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries. J. Mol. Biol. 373, 924-940 (2007).
51. Koide, A., Gilbreth, R.N., Esaki, K., Tereshko, V. & Koide, S. High-affnity single-domain binding proteins with a binary-code interface. Proc. Natl. Acad. Sci. USA 104, 6632-6637 (2007).
52. Fellouse, F.A. et al. Molecular recognition by a binary code. J. Mol. Biol. 348, 1153-1162 (2005).
53. Fellouse, F.A., Barthelemy, P.A., Kelley, R.F. & Sidhu, S.S. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J. Mol. Biol. 357, 100-114 (2006).
54. Hoppe-Seyler, F., Crnkovic-Mertens, I., Tomai, E. & Butz, K. Peptide aptamers: specifc inhibitors of protein function. Curr. Mol. Med. 4, 529-538 (2004). (Pubitemid 38961196)
55. Mayer, B.J., Jackson, P.K., Van Etten, R.A. & Baltimore, D. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12, 609-618 (1992).
56. Skorski, T. et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16, 6151-6161 (1997). (Pubitemid 27458335)
57. Koide, A. & Koide, S. Monobodies: antibody mimics based on the scaffold of the fbronectin type III domain. Methods Mol. Biol. 352, 95-109 (2007).
58. Machida, K. et al. High-throughput phosphotyrosine profling using SH2 domains. Mol. Cell 26, 899-915 (2007).